CClinicalTrials.gg
CompletedNCT03480607Updated Sep 7, 2020

Dexmedetomidine as Adjuvant for Bupivacaine in Ultrasound Guided Infraorbital Nerve Block for Cleft Lip Repair

A Phase 4 interventional study of Dexmedetomidine group and Dexamethasone group in Cleft Lip, sponsored by Mansoura University. Completed at 1 site in Egypt. Open to participants aged 1 Month to 1 Year. Per ClinicalTrials.gov, last updated 2020-09-07.

Sponsored by Mansoura University · Phase 4, Interventional, and Supportive care

Phase
Phase 4
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
1 Month to 1 Year
Sex
All
01

Study summary

To assess the efficacy of dexamethasone versus dexmedetomidine as adjuncts to bupivacaine for infra-orbital nerve block in infants undergoing cleft lip surgery.

Read the detailed description

Regarding patient registry; A prior G power analysis was done. Using the results obtained from previous studies and assuming an alpha error of 0.05 and beta error 0f 0.2 (power of the study 80 %), a sample size of 20 patients per group was calculated. A drop out 10% of cases is expected, so; 22 cases per group will be required.

Statistical analysis: Data will be analyzed through SPSS (Statistical Package for Social Sciences). Program version 22. Distribution of data will be first tested by Shapiro test. Data will be presented as mean and standard deviation (SD), median and range or numbers and percentages. For normally distributed data, unpaired t test will be used to compare between mean values of both groups. For pain and sedation scores, Mann Whitney U test will be used. Fisher's exact test will be used for comparison of categorical data. The P value ≤ 0.05 will be considered as the level of statistical significance.

02

Conditions studied

  • Cleft Lip

Browse trials for

03

Who can participate

Ages eligible
1 Month to 1 Year
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • American society of anesthesiologist (ASA) physical status I or II

Exclusion criteria

Exclusion Criteria:

  • known allergy to any of drugs used
  • coagulopathy
  • any wound or infection related to puncture site
  • major illness
  • failure to gain consent of parents.
04

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
44 participants (actual)

Study arms

  • Active comparator
    Dexmedetomidine group

    Dexmedetomidine in conjunction with bupivacaine for infra-orbital nerve block

    Drug: Dexmedetomidine group

  • Active comparator
    Dexamethasone group

    Dexamethasone in conjunction with bupivacaine f

    Drug: Dexamethasone group

Interventions

  • DrugDexmedetomidine group

    0.75 ml of 0.5% Bupivacaine in conjunction with 0.5 mcg/kg dexmedetomidine

  • DrugDexamethasone group

    0.75 ml of 0.5% Bupivacaine in conjunction with 0.1 mcg/kg dexamethasone

05

What researchers measure

Primary outcomes

  1. Postoperative FLACC scale

    FLACC scale: 0 : relaxed/ comfortable, 1-3 : mild discomfort, 4-6 : moderate discomfort, 7- 10: sever discomfort/ Pain / both,

    Time frame: for 24 hours after surgery

  2. Postoperative sedation score

    The degree of sedation will be assessed by using a three point sedation scale based on eye opening: - Alert with spontaneous eye opening 0, - Drowsy with eyes only opening in response to speech 1, - Sedated with eyes opening in response to physical stimulation 2,

    Time frame: for 4 hours after surgery

Secondary outcomes

  1. Heart rate

    (beat/min)

    Time frame: For 4 hours after induction

  2. Systolic blood pressure

    (mmHg)

    Time frame: For 4 hours after induction

  3. Postoperative nausea

    As nausea can't be detected in this age group; so we will detect only if vomiting occur or not and number of attacks.

    Time frame: for 24 hours after surgery

  4. Haematoma formation after surgery

    That will be scored as follows; Yes: there is hematoma formation or No: no hematoma formation

    Time frame: for 24 hours after surgery

  5. Postoperative vomiting

    Time frame: for 24 hours after surgery

06

Study locations

1 site
  • Mansoura University Childeren Hospital
    Mansourah, DK 050, Egypt
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03480607
Lead sponsor
Mansoura University
Responsible party
Sponsor
First posted
Mar 29, 2018
Start date
Aug 1, 2017
Primary completion
Apr 30, 2018
Completion
May 10, 2018
Last update
Sep 7, 2020

Study contacts

Enas Abd el Motlb, MD
study chair · Mansoura University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion